Background: Paraneoplastic hyper-eosinophilia associated with metastatic lung adenocarcinoma is a rare finding and has been associated with a poor prognosis when present. Early hyper-eosinophilia appearing following non-small cell lung cancer (NSCLC) treatment with immune checkpoint inhibitors (ICI) has been previously reported with contradictory outcomes. Case summary: We present the case of an elderly man with newly diagnosed metastatic lung adenocarcinoma and baseline hyper-eosinophilia, treated with pembrolizumab, and showing evidence of significant and rapid disease progression suggestive of hyper-progressive disease, worsening baseline hyper-eosinophilia, and a fatal outcome within 1 month of therapy initiation. Conclusion: Pre-treatment hyper-eosinophilia could represent a predictive factor of an unfavorable response to ICI treatment in cases of NSCLC. Additional similar cases are needed to draw a more conclusive relationship.
Campylobacter species are mostly associated with intestinal infections. Campylobacter fetus, however, can cause bacteremia and extra-intestinal infections especially in immunosuppressed patients. To the best of our knowledge, we present the second case of C. fetus causing thyroiditis and thyroid abscess in an immunocompetent young woman.
Immune Checkpoint Inhibitors (ICI) were shown to improve survival in patients with advanced non-small cell lung cancer. Nevertheless, around 10% of treated patients may have an atypical response with disastrous tumor growth and earlier death. Readily available predictors of such response are still unrevealed and desperately needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.